It's important that President Donald Trump "restrain himself" and build a relationship with Chinese President Xi Jinping, Bill Richardson said.
Oliver Pursche explains why he's still investing in this market.
Even if President Donald Trump doesn't get his agenda enacted, the market can still rise, expert David Waddell said.
You'll be a lousy investor if you try and follow what's going on in D.C. on a minute-by-minute basis, Evan Newmark says.
Fundstrat's Tom Lee explains why he likes energy and financials, and why he thinks the market may have more of a pullback.
The market is already pricing in a corporate tax cut, which means there could be trouble if those cuts don't get done, Robert Luna says.
The U.S. stock market posted its best day of the year on Wednesday. Here's why experts think it will go even higher.
Donald Trump looked presidential in his speech before Congress, but his administration still has a lot of work ahead, veteran trader Art Cashin says
Investors want to hear clarity from President Trump when he makes his first speech to a joint session of Congress on Tuesday night, market experts say.
The stock market is suffering from overconfidence, but there are still opportunities if investors know where to look, Larry Glazer says.
President Donald Trump's tax cuts will boost economic growth and push stocks even higher, Fairfax Global Markets' Paul Dietrich says.
Market sentiment is switching, Destination Wealth Management's Michael Yoshikami says.
Even if President Donald Trump’s tax policies are enacted, the stocks are still not a great risk-reward for investors, expert Michael Liss said.
On Twitter, Trump threatens Toyota with a large border tax if it builds a new plant outside the U.S.
A broader market rally and investors worried about missing the rally are positive for stocks, Michael Yoshikami says.
David Schiegoleit is expecting a 3 percent to 5 percent pullback in early 2017.
Investors need to stick to their asset allocation that's equal to their risk tolerance and age, Cathy Curtis said.
Conventional wisdom is the market rally may lose steam in the beginning of 2017, but that consensus could be wrong, one expert told CNBC on Monday.
While some may be concerned the market is moving too high too fast, veteran strategist Jeff Saut told CNBC Thursday he would still buy any dips.
Donald Trump's negotiating tactics may score him some wins, but in the long run it's going to cost him, Elevation Partners' Jeff Cohn says.
Blackstone CEO Steve Schwarzman will chair Trump's strategic and policy forum, which will feature the heads of some of the largest American companies.
Wilbur Ross is close to Donald Trump and has experience across a lot of industries, said Bill Daley, who headed up Commerce under President Bill Clinton.
The U.S. stock market's rally probably isn't anywhere near over, experts predicted Friday.
While Donald Trump has promised to revitalize the economy, Evan Newmark only sees growth coming from inflation and global trade.
Billionaire real estate mogul Jeff Greene told CNBC on Monday he has grave concerns about a Donald Trump presidency.
Analyst Jamie Albertine has questions about SolarCity's valuation and the timing of its proposed merger with Tesla.
Former DOJ official David Rivkin believes the FBI received information that puts into question its original conclusion about Hillary Clinton.
The timing of the latest Hillary Clinton email probe suggests there may be some significant information in the case, two Republican congressmen said.
It will be hard for the DOJ to oppose the AT&T-Time Warner merger, former FCC commissioner Jonathan Adelstein said.
TD Ameritrade and Toronto-Dominion Bank on Monday announced plans to acquire Scottrade Financial Services in a deal valued at about $4 billion.
The elections, earnings and energy are all driving the market, Jack Bouroudjian says, and a lot of what he's seeing isn't making him feel confident.
Stocks have been trading in a narrow range because investors are looking for clarity, UBS' Art Cashin says.
Trump advisor Peter Navarro told CNBC he has an issue with a recent report that shows Trump's plan will not benefit the economy in the long term.
Democratic Vice Presidential Nominee Tim Kaine spoke with CNBC on Tuesday afternoon.
To have a member of Congress dictate the rulemaking agenda and the schedule of the SEC is verboten, former SEC commissioner Laura Unger says.
Shareholder Mario Gabelli thinks the Redstones should give Les Moonves five years to turn around the company if CBS and Viacom merge.
If you are worried about political risk in 2017 and 2018, you need to take a Democratic sweep into account, Jimmy Pethokoukis says.
While he didn't outright endorse Donald Trump, CSX CEO Michael Ward said he likes the GOP nominee's support of the coal industry.
There is volatility in the market and that means investors have to know where to look to withstand the bumps in the road, experts say.
Donald Trump's "erratic" personality makes him a unique debate opponent, Hillary Clinton's campaign manager says.
As Clinton and Trump head into their first debate, their camps are confident that their candidate's economic plan will win the day.
London's first Muslim mayor said Americans can't let terrorists scare them into changing the way they live their lives.
The IPO market is down this year, but 2017 is looking like a more stable year, EY's Jackie Kelley says.
The stock market's recent slump may be the beginning of a move down, veteran industry insider Jack Bouroudjian said Tuesday.
A Federal Reserve interest rate hike will cause near-term reallocations in the stock market but not long-term problems, Bill Miller said Tuesday.
Vladimir Putin is taking advantage of an opportunity in U.S. politics, professor Nina Khrushcheva says.
Donald Trump's suggestion to build a wall along the U.S.-Mexico border is not only physical, but also it's symbolic, one supporter said.
Chief pharmacy officer at the Cleveland Clinic discusses Mylan's "generic" version of its own product, the Epipen, on CNBC's "Closing Bell."
Apple and other multinational companies can expect to start paying a lot more taxes in the coming years, law professor Edward Kleinbard says.
Shares of St. Jude Medical could drop to $55 or lower if the Abbott Laboratories' deal falls apart, Muddy Waters' Carson Block told CNBC Friday.